Founded in 1926 by Dr. Ilhan New, Yuhan Corporation began with a vision to restore national sovereignty through public health. Believing that a healthy population is essential for a strong nation, Dr. New established the company to provide high-quality medicines and address critical health issues in Korea. For nearly a century, Yuhan has stayed true to this mission, prioritizing research and development and building successful partnerships with global pharmaceutical companies. As a result, Yuhan has been named one of Korea’s most respected companies for 20 consecutive years.

Yuhan is also recognized for its strong commitment to social responsibility. Dr. New donated his entire personal wealth to society, and the company continues this legacy by returning a portion of its profits to community initiatives.

Research and development remains the core of Yuhan’s business. The company focuses on therapies for inflammatory, autoimmune, oncologic, and metabolic diseases, using innovative and practical approaches to improve quality of life. With FDA-compliant facilities and certifications from major global regulatory agencies, Yuhan offers end-to-end services for active pharmaceutical ingredients (APIs) and intermediates—from research to commercial production.